The Ohio burgee. (Getty images file photo.)
Every morning in the Ohio Capital Journal’s free newsletter, The Eye-Opener, we round up the news and commentary from across Ohio and around the country and world that is catching our attention. We call this feature Catching Our Eye, republished here.
Please subscribe to our free daily newsletter to get all the Ohio news you need to know right to your inbox every weekday morning.
If you already subscribe, please share with your family and friends so they know about the Ohio Capital Journal too: https://ohiocapitaljournal.com/subscribe/
GET THE MORNING HEADLINES.
Catching Our Eye
• Ohio law schools. Reuters reports, “Ohio proposal would limit ABA role in lawyer admissions.”
Ohio is poised to drop its requirement that lawyers graduate from an American Bar Association-accredited law school, joining other Republican-led states amid a backlash to the ABA’s law school oversight role under the Trump administration.
The Supreme Court of Ohio on Thursday said it has directed the court’s top administrator to develop Ohio’s own law school accreditation process and requested public comments, opens new tab on admissions rule changes that eliminate specific references to the ABA.
• The climate. The Statehouse News Bureau’s Sarah Donaldson reports, “Climate activists march from southern Ohio to Columbus.”
About two dozen hikers trekked more than 100 miles north then west the last two weeks, ending their “Great Ohio Climate March” on Thursday morning under blue skies outside the Statehouse.
Under the sun, and through bouts of floodwater left by rain, Great Ohio Climate March thru-hikers journeyed from the Athens City Pool to Salt Fork State Park in Cambridge to downtown Columbus. Around 180 hikers from Ohio and elsewhere joined them for varying legs of the march. Third Act, a national environmentalist organization of activists who are 60 and older, led the event.
• Skin cancer vaccine? NPR reports, “A cancer vaccine made just for you. mRNA is back and it’s fighting melanoma.”
At the time, mRNA technology was in the news because of the recently developed Moderna COVID-19 vaccine. This melanoma trial, which included 157 patients in Australia and the U.S., all of whom had surgery to remove their tumors, was set up to test whether the same mRNA technology could be used to create a personalized cancer vaccine, explains Dr. Janice Mehnert. Mehnert is a melanoma specialist and researcher at NYU Langone Health and senior author of a new paper published Monday analyzing the five-year results…
The results are striking. After five years of follow-up, 68.8% of patients who received the combination therapy remained cancer-free, she says, compared with 49.1% of patients who received Keytruda alone, which amounts to a 49% reduction in risk. “That’s pretty exciting,” Mehnert says.
In addition, 92% of patients who received the combination therapy were alive at the five-year mark, compared with 71% of those who only used Keytruda. “I think this is strong evidence that this therapy, when used in combination with immunotherapy, can demonstrably reduce the risk of dying from this disease,” she says.
YOU MAKE OUR WORK POSSIBLE.